- Home
- PNFP vs EXEL Comparison
PNFP vs EXEL Comparison
Compare PNFP & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PNFP | EXEL |
|---|---|---|
| Founded | 2000 | 1994 |
| Country | United States | United States |
| Employees | 3595 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 11.4B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | PNFP | EXEL |
|---|---|---|
| Price | $98.49 | $46.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 21 |
| Target Price | ★ $111.20 | $46.50 |
| AVG Volume (30 Days) | 1.2M | ★ 2.1M |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.09% | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | N/A | ★ 2.78 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | $160.52 | $13.61 |
| Revenue Next Year | $9.24 | $13.13 |
| P/E Ratio | ★ $12.24 | $16.83 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $81.08 | $33.76 |
| 52 Week High | $120.39 | $48.74 |
Technical Indicators
Market Signals| Indicator | PNFP | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 67.56 | 59.67 |
| Support Level | $92.97 | $40.53 |
| Resistance Level | $101.94 | $46.46 |
| Average True Range (ATR) | 2.44 | 1.30 |
| MACD | 0.89 | 0.19 |
| Stochastic Oscillator | 91.58 | 65.99 |
Price Performance
Historical ComparisonAbout PNFP Pinnacle Financial Partners Inc.
Pinnacle Financial Partners Inc is a financial holding company. The company operates through its wholly-owned subsidiary, Pinnacle Bank. The bank provides a full range of lending products, including commercial, real estate, and consumer loans to individuals and small to medium-sized businesses. It operates as a community bank mainly in the urban markets of Nashville, Knoxville, Memphis, and Chattanooga, Tennessee, as well as surrounding counties. It relies heavily on mergers and acquisitions. A majority of its loan portfolio is in commercial loans, mainly real estate, as well as industrial loans. The bank generates a majority of its net revenue through net interest income.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.